Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

Tools
- Tools
+ Tools

Popat, R., Plesner, T., Davies, F., Cook, G., Cook, M., Elliott, P., Jacobson, E., Gumbleton, T., Oakervee, H., Cavenagh, J. (2013) A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 160 (5). pp. 714-717. ISSN 0007-1048

Full text not available from this repository.

Item Type: Letter
Authors (ICR Faculty only): Davies, Faith
All Authors: Popat, R., Plesner, T., Davies, F., Cook, G., Cook, M., Elliott, P., Jacobson, E., Gumbleton, T., Oakervee, H., Cavenagh, J.
Additional Information: ISI Document Delivery No.: 092AW Times Cited: 0 Cited Reference Count: 9 Popat, Rakesh Plesner, Torben Davies, Faith Cook, Gordon Cook, Mark Elliott, Peter Jacobson, Eric Gumbleton, Todd Oakervee, Heather Cavenagh, Jamie Wiley-blackwell Hoboken
Uncontrolled Keywords: myeloma clinical trials renal medicine apoptosis proteins
Research teams: Closed research groups > Myeloma Targeted Treatment
Depositing User: Barry Jenkins
Date Deposited: 21 Mar 2013 16:44
Last Modified: 13 Nov 2015 16:27
URI: http://publications.icr.ac.uk/id/eprint/12341

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust